 Home > Active Ingredient News > Antitumor Therapy > AACR 2022: Results of durvalumab and tremelimumab in combination with first-line neoadjuvant chemotherapy in patients with advanced ovarian cancer (KGOG 3046/TRU-D)

AACR 2022: Results of durvalumab and tremelimumab in combination with first-line neoadjuvant chemotherapy in patients with advanced ovarian cancer (KGOG 3046/TRU-D)

 Last Update: 2022-05-19
 Source: Internet
 Author: User

Tags

lithium drug wiki

chemotherapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In January 2020, the U.

immunity

Eligible patients were assigned to the following neoadjuvant chemoimmunotherapy (NACI): original cohort 1 arm (durvalumab 1500 mg q3w + tremelimumab 75 mg q3w + paclitaxel 175 mg/㎡ + carboplatin AUC 5 [ 3 cycles]) or expansion cohort 2 (durvalumab 1500 mg q3w + tremelimumab 300 mg [1 dose] + original chemotherapy), with cohort 2 starting after completion of cohort 1

During treatment, immunological changes in the tumor microenvironment (TME) were explored by performing a series of biopsies

The results of the interim analysis, published last year, showed: A total of 23 patients were included in the study, with a median age of 60 years.

Published this time are 45 patients, as follows: group 1 (n=23) and group 2 (n=22)

After neoadjuvant immunotherapy combined with chemotherapy, immunohistochemical results showed that stromal tumor-infiltrating lymphocytes (P=0.

These data now highlight the clinical activity and manageable toxicity of durvalumab and tremelimumab added to neoadjuvant chemotherapy in advanced epithelial ovarian cancer

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.